Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines

International Journal of Oncology

Volumn 37, Issue 4, 2010, Pages 1031-1041

  Van Geelen, Caroline M M ^a   Pennarun, Bodvael ^a   Boerma Van, Wytske ^a   Le, Phuong T K ^a   Spierings, Diana C J ^a   De Vries, Elisabeth G E ^a   De Jong, Steven ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apoptosis; Caspase 8; DR4; DR5; Drug resistance; FLIP; TRAIL

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 8; CYCLOHEXIMIDE; FLICE INHIBITORY PROTEIN; PROCASPASE 8; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL SURVIVAL; CELL VIABILITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; MISMATCH REPAIR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 77956520705     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000755     Document Type: Article

References (42)

1. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995. (Pubitemid 26091143)
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690, 1996. (Pubitemid 26175834)
3. Koschny R, Walczak H and Ganten TM: The promise of TRAIL-potential and risks of a novel anticancer therapy. J Mol Med 85: 923-935, 2007.
4. Mahalingam D, Szegezdi E, Keane M, De Jong S and Samali A: TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treatment Rev 35: 280-288, 2009.
5. Oldenhuis CNAM, Stegehuis JH, Walenkamp AME, De Jong S and De Vries EGE: Targeting TRAIL death receptors. Curr Opin Pharmacol 8: 433-439, 2008.
6. Duiker EW, Mom CH, De Jong S, Willemse PH, Gietema JA, van der Zee AG and De Vries EGE: The clinical trail of TRAIL. Eur J Cancer 42: 2233-2240, 2006.
7. Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
8. Falschlehner C, Emmerich CH, Gerlach B and Walczak H: TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39: 1462-1475, 2007.
9. Le Blanc H, Lawrence D, Varfolomeev E, et al: Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8: 274-281, 2002.
10. Ionov Y, Peinado MA, Malkhosyan S, Shibata D and Perucho M: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363: 558-561, 1993. (Pubitemid 23186645)
11. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC and Perucho M: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967-969, 1997. (Pubitemid 27087710)
12. Peltomaki P: Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet 10: 735-740, 2001.
13. Burns TF and El Deiry WS: Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem 276: 37879-37886, 2001.
14. Melcher R, Koehler S, Steinlein C, et al: Spectral karyotype analysis of colon cancer cell lines of the tumor suppressor and mutator pathway. Cytogenet Genome Res 98: 22-28, 2002.
15. Van Geelen CMM, De Vries EGE, Le TKP, van Weeghel RP and De Jong S: Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. Br J Cancer 89: 363-373, 2003.
16. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001. (Pubitemid 32494397)
17. Lane D, Côté M, Grondin R, Couture M and Piché A: Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3. Mol Cancer Ther 5: 509-521, 2006.
18. Lee TJ, Lee JT, Park JW and Kwon TK: Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. Biochem Biophys Res Commun 351: 1024-1030, 2006.
19. Barnhart BC, Alappat EC and Peter ME: The CD95 type I/type II model. Semin Immunol 15: 185-193, 2003.
20. Plantivaux A, Szegezdi E, Samali A and Egan L: Is there a role for nuclear factor kappaB in tumor necrosis factor-related apoptosis- inducing ligand resistance? Ann NY Acad Sci 1171: 38-49, 2009.
21. Radhakrishnan SK and Kamalakaran S: Pro-apoptotic role of NF-kappaB: implications for cancer therapy. Biochim Biophys Acta 1766: 53-62, 2006.
22. Zhang L, Zhu H, Teraishi F, Davis JJ, Guo W, Fan Z and Fang B: Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. Neoplasia 7: 594-602, 2005.
23. Spencer SL, Gaudet S, Albeck JG, Burke JM and Sorger PK: Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459: 428-432, 2009.
24. Sussman RT, Ricci MS, Hart LS, Sun SY and El Deiry WS: Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol Ther 6: 1490-1495, 2007.
25. Zobalova R, Stantic M, Prokopova K, Dong LF and Neuzil J: Cancer cells with high expression of CD133 exert FLIP upregulation and resistance to TRAIL-induced apoptosis. Biofactors 34: 231-235, 2009.
26. Harper N, Farrow SN, Kaptein A, Cohen GM and MacFarlane M: Modulation of tumor necrosis factor apoptosis-inducing ligand-induced NF-kappa B activation by inhibition of apical caspases. J Biol Chem 276: 34743-34752, 2001.
27. Lippa MS, Strockbine LD, Le TT, Branstetter DG, Strathdee CA and Holland PM: Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells. Apoptosis 12: 1465-1478, 2007.
28. MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH and Cohen GM: Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21: 6809-6818, 2002.
29. MacFarlane M: TRAIL-induced signalling and apoptosis. Toxicol Lett 139: 89-97, 2003.
30. Ganten TM, Haas TL, Sykora J, et al: Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11 (Suppl. 1): S86-S96, 2004.
31. Pennarun B, Meijer A, De Vries EGE, Kleibeuker JH, Kruyt FA and De Jong S: Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta (BBA) - Rev Cancer 1805: 123-140, 2010.
32. Heijink DM, Kleibeuker JH, Jalving M, Boersma-van Ek W, Koornstra JJ, Wesseling J and De Jong S: Independent induction of caspase-8 and cFLIP expression during colorectal carcinogenesis in sporadic and HNPCC adenomas and carcinomas. Cell Oncol 29: 409-419, 2007. (Pubitemid 47255979)
33. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn- Dworniczak B and Debatin KM: Sensitization for death receptor-or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20: 5865-5877, 2001.
34. Harada K, Toyooka S, Shivapurkar N, et al: Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 62: 5897-5901, 2002. (Pubitemid 35204751)
35. Stegh AH, Barnhart BC, Volkland J, Algeciras-Schimnich A, Ke N, Reed JC and Peter ME: Inactivation of caspase-8 on mitochondria of Bcl-xL-expressing MCF7-Fas cells: role for the bifunctional apoptosis regulator protein. J Biol Chem 277: 4351-4360, 2002.
36. McDonald ER, III and El Deiry WS: Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proc Natl Acad Sci USA 101: 6170-6175, 2004.
37. Muro I, Hay BA and Clem RJ: The Drosophila DIAP1 protein is required to prevent accumulation of a continuously generated, processed form of the apical caspase DRONC. J Biol Chem 277: 49644-49650, 2002. (Pubitemid 36014406)
38. Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR and Ashkenazi A: Cullin3-based polyubiquitination and p62- dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 137: 721-735, 2009.
39. Hellwig C, Kohler B, Lehtivarjo A, Dussmann H, Courtney M, Prehn J and Rehm M: Real-time analysis of tumor necrosis factor-related apoptosis-inducing ligand/cycloheximide-induced caspase activities during apoptosis initiation. J Biol Chem 283: 21676-21685, 2008.
40. Bouralexis S, Findlay DM, Atkins GJ, Labrinidis A, Hay S and Evdokiou A: Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer 89: 206-214, 2003.
41. Nguyen T, Zhang XD and Hersey P: Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin Cancer Res 7: S966-S973, 2001.
42. Teitz T, Lahti JM and Kidd VJ: Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death. J Mol Med 79: 428-436, 2001. (Pubitemid 32757468)